Key result
Terazosin linked to ~15 mm Hg standing systolic blood pressure reductions in hypertension.
Why the study?
The long-term safety and efficacy of terazosin, a new selective alpha 1-adrenergic blocking agent, in essential hypertension required evaluation.
Does terazosin reduce blood pressure in patients with essential hypertension?
Observational (n=364)
Does terazosin reduce blood pressure in patients with essential hypertension?
Long-term treatment with terazosin effectively and safely reduces blood pressure in patients with essential hypertension without causing significant metabolic adverse effects.
Answers are grounded in this paper and cite their sources.
Terazosin was associated with BP reductions in essential hypertension; leaves open need for randomized confirmation before practice change.
The long-term treatment of essential hypertension with terazosin, a new once-a-day alpha 1-adrenergic blocking agent, was evaluated in 364 hypertensive patients who received total daily doses of 1 to 40 mg for 3 weeks to 56 months. Consistent mean decreases in supine and standing systolic and diastolic blood pressures were observed throughout the study for patients treated with terazosin as monotherapy (supine, 9 to 12/10 to 13 mm Hg; and standing, 12 to 18/11 to 14 mm Hg) or in combination with other antihypertensive agents (supine, 12 to 16/12 to 15 mm Hg; and standing, 16 to 22/13 to 19 mm Hg). The most commonly reported adverse experiences were dizziness, headache, asthenia, cold symptoms, and nasal congestion. Adverse effects and metabolic disorders often associated with diuretics and beta blockers such as sexual dysfunction, hyperglycemia, hyperuricemia, hypokalemia, or adverse lipid effects were seen infrequently during long-term treatment with terazosin as monotherapy. Overall, terazosin was shown to be effective, safe, and well tolerated by most patients.
No takes yet. Share an insight, caveat, or question.
Luther et al. (1988) conducted an observational in Essential Hypertension (n=364). Terazosin was evaluated on Supine and standing systolic and diastolic blood pressures. Terazosin treatment in hypertensive patients produced consistent mean decreases in supine (9-12/10-13 mm Hg) and standing (12-18/11-14 mm Hg) blood pressures.
Synapse has enriched 10 related papers. Consider them for comparative context: